A Prospective Double-Blind Study of Retrovir in Early HIV Infection

HIV Infections Clinical Trial

Official title:

A Prospective Double-Blind Study of Retrovir in Early HIV Infection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00002045
• Other study ID #: 014E
• Secondary ID: 15
• Status: Completed
• Phase: N/A
• First received: November 2, 1999
• Last updated: June 23, 2005

Study information

• Verified date: December 1989
• Source: NIH AIDS Clinical Trials Information Service
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

To evaluate the safety and tolerance of chronic administration of Retrovir (AZT) to adult patients with early manifestations of HIV disease. To assess the efficacy of AZT therapy in the treatment of HIV disease in these patients.

(12/01/89) Information supplied by drug company update. Study discontinued due to positive data from ACTG 016.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

Concurrent Treatment:

Allowed:

• Electron beam therapy to an area of less than 100 cm2.

Patient must have signs and symptoms of HIV infection confined to those of stages WRII-V or CDC groups III IV-A, IV-C-2 (except recurrent Salmonella bacteremia, nocardiosis, or disseminated/extrapulmonary Mycobacterium tuberculosis), and IV-E (except diffuse interstitial lymphoid pneumonitis).

• Patient must be able to give informed consent.

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

• Evidence of nervous system dysfunction caused by factors other than HIV infection, including chronic alcohol or drug abuse.

• Present or prior known AIDS-defining opportunistic infections, lymphomas, or malignancies based on CDC criteria.

• Present or prior known systemic opportunistic diseases most recently included in the expanded CDC definition of AIDS:

• extrapulmonary or disseminated Mycobacterium tuberculosis infections, recurrent nontyphoidal Salmonella septicemia, coccidioidomycosis, diffuse interstitial lymphoid pneumonitis.

• Evidence of compromised bone marrow function defined by specified lab values.

• Evidence of HIV neurologic disease.

• Evidence of HIV-associated "wasting syndrome".

• Hypersensitivity to zidovudine (AZT).

Concurrent Medication:

Excluded:

• Cytotoxic chemotherapeutic agents.

• Steroids.

• Interferon or immunomodulating agents.

• Any antiretroviral drug including, but not limited to zidovudine (AZT), ribavirin, HPA23, AL 721, or phosphonoformate.

Patients with the following are excluded:

• Evidence of nervous system dysfunction caused by factors other than HIV infection, including chronic alcohol or drug abuse. Present or prior known AIDS-defining opportunistic infections, lymphomas, or malignancies based on CDC criteria. Present or prior known systemic opportunistic diseases most recently included in the expanded CDC definition of AIDS:

• extrapulmonary or disseminated Mycobacterium tuberculosis infections, recurrent nontyphoidal Salmonella septicemia, coccidioidomycosis, diffuse interstitial lymphoid pneumonitis.

• Evidence of compromised bone marrow function defined by specified lab values. Evidence of HIV neurologic disease.

• Evidence of HIV-associated wasting syndrome.

• Hypersensitivity to retrovir.

Prior Medication:

Excluded within 4 weeks of study entry:

• Interferon.

• Immunomodulating agents.

• Myelosuppressive drugs.

• Nephrotoxic agents.

• Other experimental chemotherapy.

Prior Treatment:

Excluded:

• Treatment with radiation therapy (with the exception of electron beam therapy to an area of less than 100 cm2).

Chronic alcohol or drug abuse.

Study Design

Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Acquired Immunodeficiency Syndrome
• HIV Infections
• Infection

Intervention

Drug:
• Zidovudine

Locations

Country	Name	City	State
United States	Glaxo Wellcome Inc	Research Triangle Park	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Glaxo Wellcome

Country where clinical trial is conducted

United States,